hotspot -WSS

hotspot

author：leisure time 2025-10-01 02:27:33 - browse：35

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Humana CEO Bruce Broussard to step down in 2024

WSS

Drug for rare kidney disease narrowly misses mark in clinical trial

Hearing on Medicare drug price negotiation gets unusually heated

Eight reasons why you should get an updated Covid vaccine

How clinical AI models' predictive power can degrade over time

How Vertex's cystic fibrosis drug is changing patients' lives

CDC advisers recommend seasonal use of Pfizer RSV shot

knowledge

hotspot

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

A revolution in caring for preterm infants

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How Vertex's cystic fibrosis drug is changing patients' lives

Anesthesiologist group: stop taking Ozempic before surgery

Biotech stock slump in 2023: awaiting the turnaround

Walensky prepares to leave CDC — and Congress — behind

What's changing in Medicare's open enrollment this year?

Heart attack and stroke risk calculators need revising

Humana CEO Bruce Broussard to step down in 2024

focus

How clinical AI models' predictive power can degrade over time

CDC's new outbreak response network to include Northeastern

Akero's treatment for NASH falls short in cirrhosis study

Second xenotransplant done with gene

Lasker Awards 2023: Winners in biomedical research

STAT Readout: Today's biotech news includes Sana and Amylyx

leisure time

leisure time

focus

Wikipedia